Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

A Randomized, Placebo-controlled, Double-blind Phase 2 Study to Assess the Efficacy, Safety, Tolerability, and Pharmacodynamics of SPG302 in Adult Participants Diagnosed With Schizophrenia

NCT06442462 is registered in ClinicalTrials.gov with Spinogenix as lead sponsor.

NCT NCT06442462
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT06442462 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
A Randomized, Placebo-controlled, Double-blind Phase 2 Study to Assess the Efficacy, Safety, Tolerability, and Pharmacodynamics of SPG302 in Adult Participants Diagnosed With Schizophrenia
Lead sponsor
Spinogenix
Phase
Phase 2
Overall status
Active, not recruiting
Start date
August 1, 2024
Completion date
March 31, 2026
Enrollment
32 (estimated)
Sites
3

Conditions

As the registry lists them; a condition with its own page is linked.

schizophrenia